Kayelyn J. Wagner
Expertise in
18
conditions

Dr. Kayelyn J. Wagner

Hematology | Oncology
Sanford Children's Hospital Sioux Falls
1600 W. 22nd St., 
Sioux Falls, SD 
Clinical Trials:Currently Recruiting for 6 Trials
Accepting New Patients
Expertise in
18
conditions
Sanford Children's Hospital Sioux Falls
1600 W. 22nd St., 
Sioux Falls, SD 

Overview

Dr. KayeLyn Wagner specializes in pediatric oncology and blood disorders. She also serves as assistant professor of pediatrics and associate program director of the pediatric residency at the University of South Dakota Sanford School of Medicine. Speaks: English.

Dr. Wagner is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Langerhans Cell Histiocytosis, Ependymoma, Hepatoblastoma, Reticulohistiocytoma, and Bone Marrow Aspiration.

Dr. Wagner is board certified in American Board Of Pediatrics: Hematology-OncologyAmerican Board Of Pediatrics: General Pediatrics. She is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 68 clinical trials. Dr. Wagner is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in SD

Board Certifications

American Board Of Pediatrics: Hematology-OncologyAmerican Board Of Pediatrics: General Pediatrics

Fellowships

University of Iowa Children's Hospital, Pediatric Hematology/Oncology

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
Wellmark
  • HMO
  • POS
View 7 Less Insurance Carriers -

Locations

Sanford Children's Hospital Sioux Falls
1600 W. 22nd St., Sioux Falls, SD 57105
Other Locations
Sanford Aberdeen Clinic
3015 Third Ave. SE, Aberdeen, SD 57401

Additional Areas of Focus

Dr. Wagner has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

68 Clinical Trials

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 2
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
View 4 Less Clinical Trials

4 Total Publications

A Case of Neonatal Myeloid Sarcoma.
A Case of Neonatal Myeloid Sarcoma.
Journal: South Dakota medicine : the journal of the South Dakota State Medical Association
Published: March 07, 2023
Similar Doctors
Expertise in
52
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Expertise in
52
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Referral may be required

Avera Medical Group Hematology

1000 E 23rd St Ste 200, 
Sioux Falls, SD 
 (1.0 miles away)
605-322-3035
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vinod Parameswaran is a Hematologist and an Oncologist practicing medicine in Sioux Falls, South Dakota. Dr. Parameswaran is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, Thrombocytopenia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Parameswaran is currently accepting new patients.

Expertise in
49
conditions
Dr. Christopher J. Sumey
Oncology | Hematology
Expertise in
49
conditions
Dr. Christopher J. Sumey
Oncology | Hematology
Referral may be required

Sanford Cancer Center

1309 W. 17th St., 
Sioux Falls, SD 
 (0.3 miles away)
605-328-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Christopher Sumey practices hematology and oncology in Sioux Falls, South Dakota. He treats all subtypes of cancer and hematologic conditions. He has a particular interest in genitourinary malignancies, including those of the: Speaks: English. Dr. Sumey is highly rated in 49 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Sumey is board certified in American Board Of Internal MedicineAmerican Board Of Internal Medicine: Medical OncologyAmerican Board Of Internal Medicine: Hematology. Dr. Sumey is currently accepting new patients.

Expertise in
38
conditions
Dr. Steven F. Powell
Hematology | Oncology
Expertise in
38
conditions
Dr. Steven F. Powell
Hematology | Oncology
Referral may be required

Sanford Cancer Center

1309 W. 17th St., 
Sioux Falls, SD 
 (0.3 miles away)
605-328-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Steven Powell is an oncology and hematology physician who specializes in treating lung, head and neck cancer and melanoma. He is an active investigator on numerous clinical trials. Dr. Powell also runs a research lab that gives patients access to novel immunotherapy treatments for head and neck cancer. Listen to Dr. Steven Powell on Sanford Health’s Innovations podcast where he discusses fighting cancer with personalized medicine . Speaks: English. Dr. Powell is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Olfactory Neuroblastoma, Pleuropulmonary Blastoma, Melanoma, and Bone Marrow Aspiration. Dr. Powell is board certified in American Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: OncologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Powell is currently accepting new patients.

Frequently Asked Questions about Dr. Kayelyn J. Wagner

How do I make an appointment with Dr. Kayelyn J. Wagner?

You can book an appointment with Dr. Kayelyn J. Wagner by calling their office at 605-312-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kayelyn J. Wagner a top-rated expert for Langerhans Cell Histiocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kayelyn J. Wagner is classified as an Advanced expert for Langerhans Cell Histiocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kayelyn J. Wagner specialize in?

While Dr. Kayelyn J. Wagner is a Hematology, they have specific expertise in Langerhans Cell Histiocytosis, Ependymoma, and Hepatoblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kayelyn J. Wagner participate in research or clinical trials?

Yes. Dr. Kayelyn J. Wagner has published 4 articles and abstracts on conditions like Langerhans Cell Histiocytosis. You can view a list of Dr. Kayelyn J. Wagner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kayelyn J. Wagner accept my insurance?

Dr. Kayelyn J. Wagner accepts most major insurance plans, including Avera Health and Blue Cross Blue Shield. We recommend calling the office directly at 605-312-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wagner's expertise for a condition
ConditionClose
      View All 18 Advanced Conditions
      View All 21 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile